Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03868592 · ClinicalTrials.gov registry record · NA
Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis
A NA study of Obesity, Morbid, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03868592: Recruiting NA study of Obesity, Morbid, sponsored by Mayo Clinic.
NCT03868592 is a NA study of Obesity, Morbid that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 102-participant average among 19 other Obesity, Morbid trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03868592, a NA study of Obesity, Morbid, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
It is not known how much improvement in insulin regulated lipolysis (the breakdown of triglycerides) occurs following substantial, sustained weight loss. Researchers will test the effects of inflammation and lipolysis regulation in people before and after bariatric surgery (sleeve gastrectomy) to answer these questions.
Primary Outcome
Adipose tissue macrophage content as assessed by immunohistochemistry using stains for CD36, CD14 and CD206 will be done. mRNA expression for IL-6 and TNF will be measured
Conditions Studied
Interventions
- PROCEDURE Gastric sleeve/bariatric surgery
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2027-05 |
| Phase | NA |
What NCT03868592 shows while recruiting
NCT03868592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 102-participant average among 19 other Obesity, Morbid trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Obesity, Morbid appearing as the primary indexed condition, and to 1 intervention - of which Gastric sleeve/bariatric surgery is the first listed.
NCT03868592 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03868592 about?
NCT03868592 is a clinical study titled "Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis". It is not known how much improvement in insulin regulated lipolysis (the breakdown of triglycerides) occurs following substantial, sustained weight loss. Researchers will test the effects of inflammation and lipolysis regulation in people before and after bariatric surgery (sleeve gastrectomy) to an...
What is the current status of trial NCT03868592?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2019-08-01. Estimated completion is 2027-05.
What conditions does trial NCT03868592 study?
This clinical trial studies the following conditions: Obesity, Morbid.
What interventions are being tested in trial NCT03868592?
The interventions under investigation include: Gastric sleeve/bariatric surgery (PROCEDURE).
Who is sponsoring clinical trial NCT03868592?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03868592 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity, Morbid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03868592's enrollment target sits among peer trials
30 13th of 19 higher than 5 of 19 other Obesity, Morbid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity, Morbid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trans-nasal Endoscopy for Bariatric Patients
RECRUITING · NA
-
Time-restricted Eating Among Pregnant Females With Severe Obesity
RECRUITING · NA
-
Brown Adipose Tissue Activation by Spinal Cord Stimulation
RECRUITING · NA
-
Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients
RECRUITING · NA
-
Responsive Neurostimulation For Loss Of Control Eating
ACTIVE NOT RECRUITING · NA
-
Evaluation of Bariatric Endoscopic Antral Myotomy (BEAM) as a Treatment for Obesity
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI